Companies · Manufacturing
EMERYVILLE · Manufacturing · https://amyris.com/
Diligence memoA one-page analyst read on Amyris, Inc. — recommendation, valuation, rhythm, risks.→Amyris, Inc. has raised $1.6B over 46 rounds; too few niche peers to rank its valuation yet.
Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the manufacturing sector profile.
Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.
Procedural diagnosis est. — rule-based common-sense checks over the filing pattern, issuer name, activity cadence, and surfaced operating evidence.
Amyris, Inc. behaves more like a recurring private-offering issuer than a conventional venture-backed operating company.
No named principal in this company's public records yet — see all operators below.
Explore how these operators interlock with other companies in the operator network.
Amyris, Inc. is one of 3257 Manufacturing companies tracked from EMERYVILLE. By capital raised it ranks among the largest (ahead of 100% of sector peers), and in the upper tier by modeled valuation est..
Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.
AI analyst read est. — model-extracted from this company's public description, not a verified fact. 30%
operates a technology-led product inferred from public copy
Grounded in: “You are a venture analyst”
Amyris is a vertically integrated biomanufacturing company that uses renewable biological chemistry to create, customize, and manufacture high-performance molecules and advance a more prosperous and resilient world.
Amyris is a vertically integrated biomanufacturing company that uses renewable biological chemistry to create, customize, and manufacture high-performance molecules and advance a more prosperous and resilient world. At Amyris, we have pioneered the use of microbes to transform abundant plant-derived sugars into high-performing molecules at scale. Our platform unlocks access to the exquisite, sophisticated chemistry found throughout living systems – leading to new product possibilities, market opportunities, and sustainability solutions. With proven scale, we are redefining what renewable chemistry can do. Create product differentiation, competitive advantage, and lasting value with biotechnology – while reducing environmental impact and emissions. Learn about our latest updates, from our scientific breakthroughs to our collaborations with partners to transform industries.
Trades publicly as Amyris.
As reported in public records reported — not modeled.
This issuer has a dense recurring filing history, so the chart groups filings by year. Solid bars are annual reported capital reported; hatched bars show the latest modeled value est. observed in that year. Use the toggles to overlay data labels and the niche-peer / market average value lines.
Dense history compressed: 54 filings shown as 14 yearly buckets. Hover a bucket for filing count, annual capital, and latest modeled value.
The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.
This looks like a recurring offering series, so a VC stage ladder would be misleading. Showing the filed offering sequence instead.
Showing first 24 of 54 filings to keep the sequence readable.
This issuer files recurring offerings, so the model treats stage labels as a loose sizing heuristic, not a clean VC ladder. The estimate anchors on reported filing amounts and dates, then applies benchmark dilution, survival, and markup assumptions. Directional, not a quoted figure.
Benchmarked against 3257 companies in Manufacturing. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.
Raised more than 100% of sector peers (real $). Modeled value above 84% of peers (estimate).
This issuer files too frequently for VC stage labels to be meaningful, so rows are shown as initial/follow-on offerings est. instead of Pre-Seed/Seed/Series buckets.
| Stage | Amount · real | Announced | Post-money · est | Value · est | Conf. |
|---|---|---|---|---|---|
| Initial offering | $2.4M | 2008-02-07 | $11.8M | $28.9M | 85% |
| Follow-on offering | $61.1M | 2009-07-31 | $407.2M | $691.2M | 85% |
| Follow-on offering | $24.7M | 2009-07-31 | $137.5M | $271.4M | 85% |
| Follow-on offering | $47.8M | 2010-03-19 | $319.0M | $541.4M | 85% |
| Follow-on offering | $133.2M | 2010-06-21 | $1.1B | $1.5B | 85% |
| Follow-on offering | $13.8M | 2010-09-30 | $114.8M | $156.9M | 85% |
| Follow-on offering | $7.0M | 2011-10-13 | $58.3M | $79.7M | 85% |
| Follow-on offering | $58.7M | 2012-02-23 | $489.4M | $668.8M | 85% |
| Follow-on offering | $25.0M | 2012-02-27 | $208.3M | $284.7M | 85% |
| Follow-on offering | $4.1M | 2012-05-18 | $34.1M | $46.7M | 85% |
| Follow-on offering | $53.3M | 2012-07-31 | $444.2M | $607.0M | 85% |
| Follow-on offering | $38.3M | 2012-07-31 | $212.8M | $419.9M | 85% |
| Follow-on offering | $42.2M | 2012-12-24 | $352.1M | $481.2M | 85% |
| Follow-on offering | $5.0M | 2013-03-27 | $41.7M | $56.9M | 85% |
| Follow-on offering | $30.0M | 2013-06-06 | $250.0M | $341.7M | 85% |
| Follow-on offering | $10.0M | 2013-06-06 | $45.5M | $99.9M | 85% |
| Follow-on offering | $51.8M | 2013-10-16 | $345.5M | $586.4M | 85% |
| Follow-on offering | $85.9M | 2013-10-16 | $715.5M | $977.9M | 85% |
| Follow-on offering | $4.0M | 2014-04-14 | $33.3M | $45.6M | 85% |
| Follow-on offering | $10.8M | 2014-07-31 | $49.3M | $108.4M | 85% |
| Follow-on offering | $21.7M | 2014-07-31 | $180.8M | $247.1M | 85% |
| Follow-on offering | $25.0M | 2015-07-29 | $208.3M | $284.7M | 85% |
| Follow-on offering | $141.0M | 2015-07-29 | $1.2B | $1.6B | 85% |
| Follow-on offering | $57.6M | 2015-10-20 | $480.0M | $656.1M | 85% |
| Follow-on offering | $20.0M | 2016-02-12 | $166.7M | $227.8M | 85% |
| Follow-on offering | $5.0M | 2016-05-10 | $41.7M | $56.9M | 85% |
| Follow-on offering | $5.0M | 2016-06-24 | $41.7M | $56.9M | 85% |
| Follow-on offering | $2.9M | 2016-08-06 | $24.2M | $33.0M | 85% |
| Follow-on offering | $6.0M | 2016-10-21 | $50.0M | $68.3M | 90% |
| Follow-on offering | $8.5M | 2016-10-27 | $70.8M | $96.8M | 90% |
| Follow-on offering | $5.7M | 2016-11-16 | $47.7M | $65.2M | 90% |
| Follow-on offering | $25.0M | 2016-12-31 | $208.3M | $284.7M | 90% |
| Follow-on offering | $19.1M | 2017-01-11 | $159.5M | $217.9M | 90% |
| Follow-on offering | $65.2M | 2017-05-08 | $543.4M | $742.6M | 90% |
| Follow-on offering | $5.7M | 2017-05-31 | $47.5M | $64.9M | 90% |
| Follow-on offering | $25.0M | 2017-08-02 | $208.3M | $284.7M | 90% |
| Follow-on offering | $25.0M | 2017-08-02 | $208.3M | $284.7M | 90% |
| Follow-on offering | $38.1M | 2018-04-12 | $317.6M | $434.1M | 90% |
| Follow-on offering | $91.0M | 2018-08-17 | $758.1M | $1.0B | 90% |
| Follow-on offering | $7.3M | 2018-11-19 | $60.4M | $82.6M | 90% |
| Follow-on offering | $60.0M | 2018-12-06 | $500.0M | $683.3M | 90% |
| Follow-on offering | $35.6M | 2019-04-15 | $296.4M | $405.1M | 90% |
| Follow-on offering | $74.7M | 2019-04-24 | $622.4M | $850.6M | 90% |
| Follow-on offering | $9.9M | 2019-08-14 | $82.2M | $112.4M | 90% |
| Follow-on offering | $19.0M | 2019-08-28 | $158.3M | $216.4M | 90% |
| Follow-on offering | $12.5M | 2019-09-10 | $104.2M | $142.4M | 90% |
| Follow-on offering | $5.7M | 2019-10-11 | $47.8M | $65.4M | 90% |
| Follow-on offering | $7.7M | 2019-10-28 | $64.5M | $88.2M | 90% |
| Follow-on offering | $7.8M | 2019-11-14 | $65.4M | $89.4M | 90% |
| Follow-on offering | $3.9M | 2019-11-27 | $32.3M | $44.1M | 90% |
| Follow-on offering | $9.8M | 2020-01-14 | $81.3M | $111.0M | 90% |
| Follow-on offering | $93.7M | 2020-01-31 | $780.6M | $1.1B | 90% |
| Follow-on offering | $200.0M | 2020-06-05 | $1.7B | $2.3B | 90% |
| Follow-on offering | $8.0M | 2022-09-13 | $66.7M | $77.1M | 90% |
Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.
Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.
Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.
| Person | Role | Also runs | Tied since |
|---|---|---|---|
| Samir Kaul | — | 31 other | 2008-02 |
| JOHN DOERR | — | 13 other | 2008-02 |
| Geoff Duyk | — | 4 other | 2008-02 |
| L. John Doerr | — | 3 other | 2015-07 |
| Neil Renninger | — | 3 other | 2008-02 |
| John Melo | — | 2 other | 2008-02 |
| Patrick Pichette | — | 2 other | 2010-06 |
| Philippe Boisseau | — | 2 other | 2011-10 |
| Carole Piwnica | — | 1 other | 2009-07 |
| EDUARDO ALVAREZ | — | 1 other | 2018-04 |
| Fernando De Castro Reinach | — | 1 other | 2011-10 |
| Fernando Reinach | — | 1 other | 2008-02 |
| GEOFFREY DUYK | — | 1 other | 2013-10 |
| Jeryl Hilleman | — | 1 other | 2008-02 |
| Margaret Georgiadis | — | 1 other | 2016-02 |
| Peter Boynton | — | 1 other | 2010-06 |
| RAFFI ASADORIAN | — | 1 other | 2014-07 |
| Ralph Alexander | — | 1 other | 2008-02 |
| R NEIL WILLIAMS | — | 1 other | 2015-07 |
| Tamara Tompkins | — | 1 other | 2008-02 |
| ABRAHAM JOHN KLAEIJSEN | — | — | 2015-07 |
| Abraham Klaeijsen | — | — | 2016-02 |
| ANA JOHN DUTRA | — | — | 2022-09 |
| Arthur Levinson | — | — | 2010-06 |
Amyris, Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.
Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.
| Company | Sector | Stage | Raised · real | Value · est | Why similar |
|---|---|---|---|---|---|
| Elevance Renewable Sciences, Inc. | Manufacturing | Series D+ | $319.9M | $208.4M | network2 shared operators · same sector · same stage |
| Renmatix, Inc. | Manufacturing | Series C | $141.3M | $550.4M | network2 shared operators · same sector |
| S & P Ingredient Development, LLC | Manufacturing | Series B | $93.6M | $43.3M | network1 shared operator · same sector |
| V Vehicle Co | Manufacturing | Series C | $65.7M | $704.4M | network1 shared operator · same sector |
| AppLovin Corp | Gaming | Series D+ | $585.8M | $2.7B | network1 shared operator · same stage |
| Victory Innovations Holdings, LLC | Manufacturing | Series D+ | $160.0M | $99.3M | same sector · same stage |
| Guardant Health, Inc. | Biotechnology | Series D+ | $500.0M | $13.2B | network1 shared operator · same stage |
| Lightspeed POS Inc. | Other Technology | Growth/Late | $1.5B | $10.7B | network1 shared operator |
Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.
| Company | Sector | Stage | Value · est | Match |
|---|---|---|---|---|
| Amydis, Inc. | Biotechnology | Series A | $20.5M | 75% |
| Naveris, Inc. | Biotechnology | Series B | $126.9M | 75% |
| Sophiris Bio Inc. | Biotechnology | Series A | $183.2M | 74% |
| Lygos, Inc. Lygos engineers yeast to convert sugar into high-value industrial… | Biotech | Series B | $432.7M | 73% |
| Artiva Biotherapeutics, Inc. | Biotechnology | Series D+ | $4.0B | 73% |
| MatriSys Bioscience, Inc. | Biotechnology | Series A | $113.7M | 73% |
| Cascade Biocatalysts, Inc. | Biotechnology | Series A | $16.8M | 73% |
| TeVido BioDevices, Inc. | Biotechnology | Seed | $63.1M | 72% |
See where Amyris, Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.
If you work at Amyris, Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.
Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.